Literature DB >> 24568981

Comparison of SureSight autorefractor and plusoptiX A09 photoscreener for vision screening in rural Honduras.

David I Silbert1, Noelle S Matta2, Amanda L Ely3.   

Abstract

PURPOSE: To evaluate the SureSight autorefractor and compare it to the plusoptiX A09 photoscreener in the detection of amblyopia risk factors in a cohort of Honduran children examined during medical mission work and to assess the utility of both devices in the rural setting.
METHODS: The medical records of patients who had undergone SureSight autorefractor screening, plusoptiX photoscreening, and a gold standard pediatric ophthalmology examination, including cycloplegic refraction, during a recent medical mission trip to Honduras were retrospectively reviewed.
RESULTS: A total of 216 children were examined. Of these, 9 (4%) were found to have amblyopia risk factors based on the current referral criteria of the American Association for Pediatric Ophthalmology and Strabismus on ophthalmological examination. The plusoptiX was found to have 89% sensitivity and 80% specificity; the SureSight, using manufacturer's referral criteria, was found to have sensitivity of 89% and specificity of 71%.
CONCLUSIONS: Both devices were found to be reliable vision screening devices when used on the general population of remote villages in Honduras, although the specificity of the plusoptiX A09 was higher.
Copyright © 2014 American Association for Pediatric Ophthalmology and Strabismus. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24568981     DOI: 10.1016/j.jaapos.2013.09.006

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  9 in total

1.  Accuracy of the Spot and Plusoptix photoscreeners for detection of astigmatism.

Authors:  Mabel Crescioni; Joseph M Miller; Erin M Harvey
Journal:  J AAPOS       Date:  2015-10       Impact factor: 1.220

2.  Vision screening using a smartphone platform.

Authors:  Iara Debert; Douglas Rodrigues da Costa; Mariza Polati; Janaina Guerra Falabretti; Remo Susanna Junior
Journal:  Rev Paul Pediatr       Date:  2022-05-06

3.  The effectiveness of the Spot Vision Screener in detecting amblyopia risk factors.

Authors:  Mae Millicent W Peterseim; Carrie E Papa; M Edward Wilson; Jennifer D Davidson; Maria Shtessel; Mavesh Husain; Edward W Cheeseman; Bethany J Wolf; Rupal Trivedi
Journal:  J AAPOS       Date:  2014-12       Impact factor: 1.220

4.  Photoscreeners in the pediatric eye office: compared testability and refractions on high-risk children.

Authors:  Mae Millicent W Peterseim; Carrie E Papa; M Edward Wilson; Edward W Cheeseman; Bethany J Wolf; Jennifer D Davidson; Rupal H Trivedi
Journal:  Am J Ophthalmol       Date:  2014-08-01       Impact factor: 5.258

Review 5.  Advantages, limitations, and diagnostic accuracy of photoscreeners in early detection of amblyopia: a review.

Authors:  Irene Sanchez; Sara Ortiz-Toquero; Raul Martin; Victoria de Juan
Journal:  Clin Ophthalmol       Date:  2016-07-22

6.  Instrument Referral Criteria for PlusoptiX, SPOT and 2WIN Targeting 2021 AAPOS Guidelines.

Authors:  Robert Arnold; David Silbert; Heather Modjesky
Journal:  Clin Ophthalmol       Date:  2022-02-25

7.  Comparative Validation of PlusoptiX and AI-Optic Photoscreeners in Children with High Amblyopia Risk Factor Prevalence.

Authors:  Robert W Arnold
Journal:  Clin Ophthalmol       Date:  2022-08-16

8.  Instrument referral criteria for PlusoptiX and SureSight based on 2021 AAPOS guidelines: A population-based study.

Authors:  Qi Yan; Rui Li; YingXiao Qian; Xiao Lin; Hui Zhu; Yue Wang; Xiaoyan Zhao; Xiaohan Zhang; Qigang Sun; Qingfeng Hao; Haohai Tong; Yue Zhu; Zhitong Li; Yan Zhu; Hu Liu; Dan Huang
Journal:  Front Public Health       Date:  2022-09-26

9.  To assess the accuracy of Plusoptix S12-C photoscreener in detecting amblyogenic risk factors in children aged 6 months to 6 years in remote areas of South India.

Authors:  Kirandeep Kaur; Veena Kannusamy; Fredrick Mouttapa; Bharat Gurnani; Rengaraj Venkatesh; Anjali Khadia
Journal:  Indian J Ophthalmol       Date:  2020-10       Impact factor: 1.848

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.